AriBio is a biopharmaceutical company based in South Korea focused on developing novel therapeutics for neurodegenerative and infectious diseases. AriBio uses its ARIDD drug development platform to develop polypharmacological therapeutic agents to treat multi-factorial diseases. Currently, AriBio is running a Phase 2 study for Alzheimer's disease with AR1001, a small molecule, in the United States.